Avant Brands Resultados de beneficios anteriores
Pasado controles de criterios 0/6
Avant Brands's earnings have been declining at an average annual rate of -0.7%, while the Pharmaceuticals industry saw earnings growing at 13.1% annually. Revenues have been growing at an average rate of 41% per year.
Información clave
-0.7%
Tasa de crecimiento de los beneficios
21.5%
Tasa de crecimiento del BPA
Crecimiento de la industria Pharmaceuticals | 7.3% |
Tasa de crecimiento de los ingresos | 41.0% |
Rentabilidad financiera | -32.8% |
Margen neto | -51.0% |
Última actualización de beneficios | 31 Aug 2024 |
Actualizaciones de resultados anteriores recientes
Recent updates
Desglose de ingresos y gastos
Cómo gana y gasta dinero Avant Brands. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).
Historial de beneficios e ingresos
Fecha | Ingresos | Beneficios | Gastos G+A | Gastos de I+D |
---|---|---|---|---|
31 Aug 24 | 30 | -15 | 12 | 0 |
31 May 24 | 28 | -11 | 12 | 0 |
29 Feb 24 | 27 | -8 | 11 | 0 |
30 Nov 23 | 26 | -5 | 12 | 0 |
31 Aug 23 | 29 | -4 | 11 | 0 |
31 May 23 | 27 | -3 | 9 | 0 |
28 Feb 23 | 23 | -7 | 12 | 0 |
30 Nov 22 | 20 | -8 | 11 | 0 |
31 Aug 22 | 15 | -10 | 11 | 0 |
31 May 22 | 13 | -14 | 10 | 0 |
28 Feb 22 | 12 | -12 | 7 | 0 |
30 Nov 21 | 9 | -11 | 6 | 0 |
31 Aug 21 | 9 | -11 | 5 | 0 |
31 May 21 | 9 | -9 | 5 | 0 |
28 Feb 21 | 8 | -8 | 5 | 0 |
30 Nov 20 | 8 | -10 | 5 | 0 |
31 Aug 20 | 7 | -4 | 5 | 0 |
31 May 20 | 6 | -6 | 6 | 0 |
29 Feb 20 | 5 | -8 | 7 | 0 |
30 Nov 19 | 2 | -10 | 9 | 0 |
31 Aug 19 | 1 | -11 | 10 | 0 |
31 May 19 | 0 | -11 | 11 | 0 |
28 Feb 19 | 0 | -10 | 10 | 0 |
30 Nov 18 | 0 | -11 | 10 | 0 |
Ingresos de calidad: 1BU is currently unprofitable.
Margen de beneficios creciente: 1BU is currently unprofitable.
Análisis del flujo de caja libre vs. Beneficios
Análisis del crecimiento de los beneficios en el pasado
Tendencia de beneficios: 1BU is unprofitable, and losses have increased over the past 5 years at a rate of 0.7% per year.
Acelerando crecimiento: Unable to compare 1BU's earnings growth over the past year to its 5-year average as it is currently unprofitable
Beneficios vs. Industria: 1BU is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (28.7%).
Rentabilidad financiera
Alta ROE: 1BU has a negative Return on Equity (-32.84%), as it is currently unprofitable.